BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9506245)

  • 1. Rabeprazole.
    Prakash A; Faulds D
    Drugs; 1998 Feb; 55(2):261-7; discussion 268. PubMed ID: 9506245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
    Fitton A; Wiseman L
    Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
    Barth J; Hahne W
    Aliment Pharmacol Ther; 2002 Mar; 16 Suppl 1():31-3. PubMed ID: 11849125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
    Yang KC; Wang GM; Chen JH; Chen TJ; Lee SC
    J Formos Med Assoc; 2003 Dec; 102(12):857-62. PubMed ID: 14976565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
    Hizawa K; Nakahara T; Yano Y; Inuzuka S; Akagi K; Matsumoto T
    J Clin Gastroenterol; 2000 Dec; 31(4):338-9. PubMed ID: 11129280
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
    Stack WA; Knifton A; Thirlwell D; Cockayne A; Jenkins D; Hawkey CJ; Atherton JC
    Am J Gastroenterol; 1998 Oct; 93(10):1909-13. PubMed ID: 9772054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the pharmacology of rabeprazole.
    Williams MP; Pounder RE
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
    Lüth S; Teyssen S; Kölbel CB; Singer MV
    Z Gastroenterol; 2001 Apr; 39(4):279-81, 284-5. PubMed ID: 11367976
    [TBL] [Abstract][